arrow attorney-female attorney-male btn-close btn-menu checkmark document facebook g-plus linkedin logo play search twitter
COVID-19 - Learn More
Call 24/7 (877) 562-0000
  • Search
  • About Cory Watson
    • Our Attorneys
    • Partnership Opportunities
    • Testimonials
    • News
    • Blog
    • Cory Watson Cares
  • Cases We Handle
    • Nationwide
    • Alabama
    • Tennessee
  • Contact Us
    • Nationwide
    • Birmingham
    • Memphis
    • Nashville

FDA Delays Rule on Generic Drug Labels Until 2017

Cory Watson AttorneysBy Cory Watson Attorneys | May 26th, 2016

The Food and Drug Administration (FDA) has again delayed a decision on whether generic drug makers will be held responsible for warning patients about the risks of their medications. This comes as a disappointment to trial lawyers and consumer groups who want to eliminate the legal loophole which prevents patients from suing generic drug manufacturers for dangerous generic drugs.

The majority of prescription drugs dispensed in the U.S. are generic drugs, and the companies that market them are not subject to the same warning label rules as their name brand counterparts. To get a generic drug approved for sale in the U.S., the generic drug manufacturer must prove that their generic is chemically identical to the name brand, and the label on the generic drug is identical to the one on the name brand drug. Generic drug manufacturers are not required to do any testing on the drug or update the use, safety and warning information as new medical and scientific information is learned unless the brand name drug manufacturer first updates the label information.

This regulatory scheme creates very serious health dangers to consumers using generic drugs.  First, if the brand name drug is defective, then the generic equivalent is also defective, but most courts hold that only the name brand drug manufacturer can be sued and held responsible. So, the patients taking the generic equivalents have no lawsuit when harmed by the defective generic.

Second, when a brand name drug is no longer made and sold, the brand name drug company is no longer responsible for researching and updating safety information. This means that if the drug is still available as a generic only, there is no company doing the research and updating the safety information. So if new dangers about the drug are learned, this information is not provided to the consumer by any manufacturer.

The FDA’s decision is troubling. Dr. Michael Carome, speaking as director of the Public Citizen’s Health Research Group, said, “The F.D.A. is plainly bowing to industry pressure and, in the process, prioritizing industry profits over patient health and safety.” Dr. Carome is one of many consumer advocates who had hoped the FDA would fix this safety and accountability gap.

Generic drug manufacturers object to a change in the industry standard, saying that it would create confusion as equivalent drugs could have different warning labels. Manufacturers have proposed an alternative in which the FDA would be responsible for making decisions regarding label changes. However, consumer advocates have pointed out that the agency does not test drugs and does not have the resources to monitor new developments in drug safety information.

Please join Cory Watson Attorneys in supporting safer drug labeling.

Categories

  • Abilify (2)
  • Asbestos (6)
  • Car Accidents (75)
  • Class Actions (9)
  • Community (29)
  • Cory Watson Attorneys (32)
  • Dangerous Drugs (28)
  • Defective Products (63)
  • Drug Litigation (23)
  • DuPont C8 (7)
  • Environmental (22)
  • Essure Birth Control (5)
  • Firm News (7)
  • Food Poisoning (1)
  • Industry News (13)
  • Legal Guide (9)
  • Legionnaires' Disease (9)
  • Medical Malpractice (1)
  • Mesothelioma (6)
  • Personal Injuries (43)
  • Product Liability (18)
  • Sexual Assault (23)
  • Talcum Powder Cancer (11)

Subscribe to Our Blog

Loading

Contact Our 24/7 Nationwide Lawyers

  • This field is for validation purposes and should be left unchanged.
 

Memphis, TN

Cory Watson Attorneys
254 Court Avenue, Suite 511
Memphis TN, 38103, USA

Local (901) 402-2000
Nationwide (877) 562-0000

View Location

Birmingham, AL

Cory Watson Attorneys
2131 Magnolia Ave S
Birmingham, AL 35205, USA

Local (205) 328-2200
Nationwide (877) 562-0000

View Location

Nashville, TN

Cory Watson Attorneys
1033 Demonbreun St., Ste. 300
Nashville, TN 37203, USA

Local (615) 205-0000
Nationwide (877) 562-0000

View Location

Subscribe to our newsletter

  • Blog
  • Careers
  • Disclaimer
  • Privacy Policy

Alabama Rules of Professional Conduct require the following disclaimer: Case descriptions, recoveries and testimonials presented here are not an indication of future results. Every case is different and must be evaluated on its own facts and circumstances as they apply to the law. Litigation outcome and valuation depend on many factors including jurisdiction, venue, witnesses, parties, testimony and documentary evidence. Furthermore, no representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers.

Law Firm Marketing by cj Advertising

Inquire NowRequest Free Consultation
Free Consultation Form
  • This field is for validation purposes and should be left unchanged.
fbq('track', 'PageView');